Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5XJ7F
|
|||
| Drug Name |
NDI-034858
|
|||
| Synonyms |
Zasocitinib; NDI-034858; C293MNS6TQ; 2272904-53-5; UNII-C293MNS6TQ; TAK-279; Pyrazolo(1,5-a)pyrimidine-3-carboxamide, N-((1R,2R)-2-methoxycyclobutyl)-7-(methylamino)-5-((2-oxo(1(2H),2'-bipyridin)-3-yl)amino)-; (8S)-N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5-{[(1P,2'P)-2-oxo-2H-[1,2'-bipyridin]-3-yl]amino}pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-((1R,2R)-2-Methoxycyclobutyl)-7-(methylamino)-5-((2-oxo-2H-[1,2'-bipyridin]-3-yl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxamide; zasocitinib [INN]; TAK279; SCHEMBL20678921; GTPL12155; BDBM424361; EX-A7221; NDI034858; US10508120, Compound I-816; US10508120, Compound I-908; MS-28444; HY-150096; CS-0609920; compound I-908 [US20190256519A1]; F96153; N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5- [(2-oxo[1(2H),2'-bipyridin]-3-yl)amino]-pyrazolo[1,5- a]pyrimidine-3-carboxamide; N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5-[(2-oxo-1-pyridin-2-ylpyridin-3-yl)amino]pyrazolo[1,5-a]pyrimidine-3-carboxamide; ZSB
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Psoriatic arthritis [ICD-11: FA21; ICD-9: 696] | Phase 2 | [1] | |
| Company |
Nimbus Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H24N8O3
|
|||
| Canonical SMILES |
CNC1=CC(=NC2=C(C=NN12)C(=O)NC3CCC3OC)NC4=CC=CN(C4=O)C5=CC=CC=N5
|
|||
| InChI |
InChI=1S/C23H24N8O3/c1-24-20-12-18(27-16-6-5-11-30(23(16)33)19-7-3-4-10-25-19)29-21-14(13-26-31(20)21)22(32)28-15-8-9-17(15)34-2/h3-7,10-13,15,17,24H,8-9H2,1-2H3,(H,27,29)(H,28,32)/t15-,17-/m1/s1
|
|||
| InChIKey |
BWINBHTTZLVXGT-NVXWUHKLSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05153148) A Phase 2b, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects With Active Psoriatic Arthritis. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Nimbus Therapeutics | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.